---
document_datetime: 2025-07-08 09:50:14
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/holoclar-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: holoclar-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6062515
conversion_datetime: 2025-12-26 20:27:04.844121
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Holoclar

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 07/07/2025                          |                                             | Annex II                         | To amend a misalignment of the Risk Management |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000262697                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To amend a misalignment of the Risk Management Plan Annex 6 related to the completion of the HOLOSIGHT clinical trial enrolment. RMP Annex 6 still included a reference to informing and encouraging about the registration in the safety study registry in the key elements. This reference is proposed now for deletion to ensure harmonisation with the RMP body (approved in the 2023 renewal procedure EMEA/H/C/002450/R/0058) and the Educational materials (updated via type IB variation EMEA/H/C/002450/IB/0067). The Product Information Annex II has been updated in accordance for all languages. In addition, the marketing authorization holder has taken the opportunity to correct a   |            |     | Plan Annex 6 related to the completion of the HOLOSIGHT clinical trial enrolment. RMP Annex 6 still included a reference to informing and encouraging about the registration in the safety study registry in the key elements. This reference is proposed now for deletion to ensure harmonisation with the RMP body (approved in the 2023 renewal procedure EMEA/H/C/002450/R/0058) and the Educational materials (updated via type IB variation EMEA/H/C/002450/IB/0067). The Product Information Annex II has been updated in accordance for all languages.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000265797 | This was an application for a group of variations. B.II.c) Control of excipients - B.II.c.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 15/05/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| B.II.c) Control of excipients - B.II.c.z Other variation - Accepted   |
|-----------------------------------------------------------------------|